Previous 10 | Next 10 |
Arrowhead's stock dropped 25% on preliminary update from ongoing chronic toxicology study in rats causing voluntary pause. However, further safety data released later on could possibly reverse this. While safety issue noted with ARO-ENaC for Cystic Fibrosis, there's another clinical c...
The following slide deck was published by Vir Biotechnology, Inc. in conjunction with this event. For further details see: Vir Biotechnology (VIR) Presents At EASL ILC 2021 Hepatitis B Data Call Presentation
GlaxoSmithKline (NYSE: GSK) and Vir Biotechnology (NASDAQ: VIR) recently reported results from a confirmatory study evaluating antibody therapy sotrovimab in treating non-hospitalized COVID-19 patients. In this Motley Fool Live video recorded on June 23, 2021 , Motle...
Dr_Microbe/iStock via Getty Images GlaxoSmithKline ([[GSK]] -0.1%) and Vir Biotechnology ([[VIR]] -0.4%) have signed an advance purchase agreement with the Singapore Ministry of Health for their monoclonal antibody therapy Sotrovimab, The Straits Times reports. Subject to on-time de...
bloodua/iStock via Getty Images The European Commission has selected five medications that its considers preferred therapies in the treatment of COVID-19, Reuters reports. The medicines include Eli Lilly (LLY) and Incyte's (INCY) Oluminant (baricitinib), Regeneron's (REGN) REGN-COV2 (casirivi...
Dr_Microbe/iStock via Getty Images On Tuesday, the European Commission listed four monoclonal antibody treatments and a repurposed drug against COVID-19 as it plans to create an initial portfolio of preferred drugs for the disease, Reuters reports. With the selection, the regional body a...
Arbutus presented five abstracts at EASL International Liver Congress 2021, one presentation dealing with long-term dosing of AB-729 for Hepatitis B patients was given as a late-breaker oral presentation. 60 mg AB-729 given once every four weeks had achieved a similar HBsAg decline fo...
brightstars/iStock via Getty Images Last week, Vir Biotechnology (VIR) announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with Hepatitis B virus ((HBV)) infection. Commenting on results, Bank of America analysts led by Geoff Mea...
The U.S. Department of Health and Human Services ((HHS)) has paused the distribution of bamlanivimab and etesevimab antibody combination developed by Eli Lilly ([[LLY]] -1.1%) as a treatment for COVID-19.The decision jointly taken by the Assistant Secretary for Preparedness and Resp...
ALENA DZIHILEVICH/iStock via Getty Images Vir Biotechnology (VIR) perks up 3% premarket after announcing new data from its ongoing Phase 2 clinical trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus ((HBV)) infection. The results,...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...